Chardan Capital Maintains Buy on Centessa Pharmaceuticals, Maintains $30 Price Target

Benzinga · 07/30/2025 22:05
Chardan Capital analyst Rudy Li maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $30 price target.